A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

计划入组 128 人 · 首次发布于 2017 年 5 月 11 日

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

计划入组 1,054 人 · 首次发布于 2018 年 1 月 10 日

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

计划入组 599 人 · 首次发布于 2021 年 3 月 29 日

2-mercaptobenzothiazole

C₇H₅NS₂

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Talazoparib Plus Enzalutamide Demonstrates Overall Survival Benefit in mCRPC

TALAPRO-2 Trial: Talazoparib-Enzalutamide Combo Shows Significant Survival Benefit in Metastatic Prostate Cancer

TALAPRO-2 Trial Explores Talazoparib Combination in Metastatic Prostate Cancer